Metabolic-associated fatty liver disease: Difficulties in diagnostics and ways to overcome them

1. Клинические рекомендации. Неалкогольная жировая болезнь печени. Российская ассоциация эндокринологов, Российская гастроэнтерологическая ассоциация, общероссийская общественная организация «Российское научное медицинское общество терапевтов», общероссийская общественная организация «Российская ассоциация геронтологов и гериатров», Российское общество по изучению печени, Российское общество профилактики неинфекционных заболеваний, Национальное общество профилактической кардиологии. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 748_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/748_2 (дата обращения – 15.07.2025). (Clinical guidelines. Non-alcoholic fatty liver disease. Russian Association of Endocrinologists, Russian Gastroenterological Association, Russian scientific medical society of internal medicine, Russian Association of Gerontologists and Geriatrics, Russian Society for the Study of the Liver, Russian Society for the Prevention of Non-Infectious Diseases, National Society for Preventive Cardiology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 748_2. URL: https://cr.minzdrav.gov.ru/preview-cr/748_2 (date of access – 15.07.2025) (In Russ.)).

2. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16.

PMID: 32258520. PMCID: PMC7063528. https://doi.org/10.21037/tgh.2019.09.08

3. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019;70(3):531–44.

PMID: 30414863. https://doi.org/10.1016/j.jhep.2018.10.033

4. Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К. с соавт. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31–41. (Ivashkin VT, Drapkina OM, Maev IV, Trukhmanov AS, Blinov DV, Palgova LK et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Rossiiskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31–41 (In Russ.)). EDN: VOXFQP.

5. Лазебник Л.Б., Голованова Е.В., Туркина С.В., Райхельсон К.Л., Оковитый С.В., Драпкина О.М. с соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;(1):4–52. (Lazebnik LB, Golovanova EV, Turkina SV, Raikhelson KL, Okovitiy SV, Drapkina OM et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021;(1):4–52 (In Russ.)).

EDN: KJLOJV. https://doi.org/10.31146/1682-8658-ecg-185-1-4-52

6. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Умярова Р.М. Метаболически ассоциированная жировая болезнь печени. М.: Прима Принт. 2021; 72 с. (Maev IV, Andreev DN, Kucheryaviy YuA, Umyarova RM. Metabolically associated fatty liver disease. Moscow: Prima Print. 2021; 72 pp. (In Russ.)). ISBN: 978-5-6044392-9-6. EDN: AZIBOK.

7. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–9.

PMID: 32278004. https://doi.org/10.1016/j.jhep.2020.03.039

8. Цуканов В.В., Васютин А.В., Тонких Ю.Л. Новые аспекты неалкогольной жировой болезни печени. Доктор.Ру. 2021;20(4):33–39. (Tsukanov VV, Vasyutin AV, Tonkikh YuL. New aspects of non-alcoholic fatty liver disease. Doctor.Ru. 2021;20(4):33–39 (In Russ.)).

EDN: CFFIRM. https://doi.org/10.31550/1727-2378-2021-20-4-33-39

9. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542.

PMID: 38851997. https://doi.org/10.1016/j.jhep.2024.04.031

10. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56.

PMID: 37364790. https://doi.org/10.1016/j.jhep.2023.06.003

11. Chen BR, Pan CQ. Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2022;46(1):101755.

PMID: 34311134. https://doi.org/10.1016/j.clinre.2021.101755

12. Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68(2):763–72.

PMID: 29356032. PMCID: PMC6054824. https://doi.org/10.1002/hep.29797

13. Ferraioli G. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason (2001). 2021;48(4):489–95.

PMID: 34132934. PMCID: PMC8578057. https://doi.org/10.1007/s10396-021-01106-1

14. Тарасова О.И., Кухарева Е.И., Красницкая С.К., Мазурчик Н.В., Нгамени М.Я., Малинина Н.А. с соавт. Оценка эффективности ультразвуковой сдвиговой эластометрии и стеатометрии печени. Терапевтический архив. 2020;92(4):17–22. (Tarasova OI, Kukhareva EI, Krasnitskaya SK, Mazurchik NV, Ngameni MYa, Malinina NA et al. Evaluation of the effectiveness of ultrasound shear elastography and liver steatometry. Therapeutic Archive. 2020;92(4):17–22 (In Russ.)).

EDN: UIHWZK. https://doi.org/10.26442/00403660.2020.04.000497

15. Широкова Е.Н., Павлов Ч.С., Карасева А.Д., Алиева А.М., Седова А.В., Ивашкин В.Т. Эластография в диагностике неалкогольной жировой болезни печени. Вестник Российской академии медицинских наук. 2019;74(1):5–13. (Shirokova EN, Pavlov ChS, Karaseva AD, Alieva AM, Sedova AV, Ivashkin VT. Elastography in the diagnosis of non-alcoholic fatty liver disease. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2019;74(1):5–13 (In Russ.)).

EDN: PSZWNI. https://doi.org/10.15690/vramn1071

16. Бакулин И.Г., Абациева М.П. Неинвазивные методы в диагностике неалкогольной жировой болезни печени. Медико-социальная экспертиза и реабилитация. 2017;20(2):107–112. (Bakulin IG, Abatsieva MP. Non-invasive methods in the diagnosis of nonalcoholic fatty liver disease. Mediko-sotsialnaya ekspertiza i reabilitatsiya = Medical and Social Expert Evaluation and Rehabilitation. 2017;2(20):107–112 (In Russ.)).

EDN: YUHNKP. https://doi.org/10.18821/1560-9537-2017-20-2-107-112

17. Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance? J Gastroenterol Hepatol. 2013;28(7):1194–1201.

PMID: 23425053. https://doi.org/10.1111/jgh.12134

18. Suzuki K, Yoneda M, Imajo K, Kirikoshi H, Nakajima A, Maeda S, Saito S. Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. Hepatol Res. 2013;43(9):979–83.

PMID: 23294411. https://doi.org/10.1111/hepr.12039

19. Lupșor-Platon M, Feier D, Stefănescu H, Tamas A, Botan E, Sparchez Z et al. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: A prospective study. J Gastrointestin Liver Dis. 2015;24(1):35–42.

PMID: 25822432. https://doi.org/10.15403/jgld.2014.1121.mlp

20. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–607.e2.

PMID: 27911262. PMCID: PMC5285304. https://doi.org/10.1053/j.gastro.2016.10.026

21. Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67(4):1348–59.

PMID: 29108123. PMCID: PMC5867216. https://doi.org/10.1002/hep.29639

22. Ferraioli G, Monteiro LBS. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–62.

PMID: 31686762. PMCID: PMC6824276. https://doi.org/10.3748/wjg.v25.i40.6053

23. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30.

PMID: 30689971. https://doi.org/10.1053/j.gastro.2019.01.042

24. Cao Y-T, Xiang L-L, Qi F, Zhang Y-J, Chen Y, Zhou X-Q. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. EClinicalMedicine. 2022;51:101547.

PMID: 35844772. PMCID: PMC9284399. https://doi.org/10.1016/j.eclinm.2022.101547

25. Sasso M, Audière S, Kemgang A, Gaouar F, Corpechot C, Chazouillères O et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: A pilot study assessing diagnostic accuracy. Ultrasound Med Biol. 2016;42(1):92–103.

PMID: 26386476. https://doi.org/10.1016/j.ultrasmedbio.2015.08.008

26. Friedrich-Rust M, Hadji-Hosseini H, Kriener S, Herrmann E, Sircar I, Kau A et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol. 2010;20(10):2390–96.

PMID: 20526777. https://doi.org/10.1007/s00330-010-1820-9

27. Wong VW-S, Vergniol J, Wong GL-H, Foucher J, Chan AW-H, Chermak F et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107(12):1862–71.

PMID: 23032979. https://doi.org/10.1038/ajg.2012.331

28. Fouad Y, Alboraie M, Shiha G. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2024;18(Suppl 2):827–33.

PMID: 38967907. PMCID: PMC11450050. https://doi.org/10.1007/s12072-024-10704-3

29. Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382–90.

PMID: 33541866. https://doi.org/10.1136/gutjnl-2020-322564

30. Sato-Espinoza K, Chotiprasidhi P, Huaman MR, Díaz-Ferrer J. Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol. 2024;16(3):452–64.

PMID: 38577539. PMCID: PMC10989317. https://doi.org/10.4254/wjh.v16.i3.452

31. Leung JC-F, Loong TC-W, Wei JL, Wong GL-H, Chan AW-H, Choi PC-L et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65(1):54–64.

PMID: 27339817. https://doi.org/10.1002/hep.28697

32. Patel AH, Peddu D, Amin S, Elsaid MI, Minacapelli CD, Chandler T-M et al. Nonalcoholic fatty liver disease in lean/nonobese and obese individuals: A comprehensive review on prevalence, pathogenesis, clinical outcomes, and treatment. J Clin Transl Hepatol. 2023;11(2):502–15.

PMID: 36643037. PMCID: PMC9817050. https://doi.org/10.14218/JCTH.2022.00204

33. Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr. 2019;38(3):975–81.

PMID: 30466956. https://doi.org/10.1016/j.clnu.2018.08.008

34. Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329–41.

PMID: 32039383. PMCID: PMC7001558. https://doi.org/10.1016/j.jhepr.2019.08.002

35. Буеверов А.О., Богомолов П.О. Неалкогольная жировая болезнь печени без ожирения: проблема, ожидающая решения. Терапевтический архив. 2017;89(12-2):226–32. (Bueverov AO, Bogomolov PO. Nonalcoholic fatty liver disease without obesity: The problem to be solved. Terapevticheskiy arkhiv = Therapeutic Archive. 2017;89(12-2):226–32 (In Russ.)).

EDN: YPOPRY. https://doi.org/10.17116/terarkh20178912226-232

36. Chan W-K. Comparison between obese and non-obese nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S58–S67.

PMID: 36472052. PMCID: PMC10029940. https://doi.org/10.3350/cmh.2022.0350

37. Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2017;2(1):48–57.

PMID: 29404512. PMCID: PMC5776871. https://doi.org/10.1002/hep4.1124

38. Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022;16(2):290–99.

PMID: 34238770. PMCID: PMC8924809. https://doi.org/10.5009/gnl210084

39. Цуканов В., Тонких Ю., Каспаров Э., Куперштейн Е., Амельчугова О., Лукичева Э., Васютин А. Неалкогольная жировая болезнь печени у взрослого городского населения России (распространенность и факторы риска). Врач. 2010;(9):2–6. (Tsukanov V, Tonkikh Yu, Kasparov E, Kupershtein E, Amelchugova O, Lukicheva E, Vasyutin A. Nonalcoholic fatty liver disease in the adult urban population of Russia: prevalence and risk factors. Vrach = The Doctor. 2010;(9):2–6 (In Russ.)). EDN: MWJSAD.

40. Евстифеева С.Е., Шальнова С.А., Куценко В.А., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. с соавт. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):40–49. (Evstifeeva SE, Shalnova SA, Kutsenko VA, Yarovaya EB, Balanova YuA, Imaeva AE et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: Associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022;21(9):40–49 (In Russ.)).

EDN: SITSBL. https://doi.org/10.15829/1728-8800-2022-3356